Dian Diagnostics Group Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021
August 25, 2021 at 07:42 am EDT
Share
Dian Diagnostics Group Co.,Ltd. announced earnings results for the half year ended June 30, 2021. For the half year, the company announced sales was CNY 5,791.213 million compared to CNY 4,473.346 million a year ago. Operating income was CNY 1,033.816 million compared to CNY 692.545 million a year ago. Net income was CNY 727.088 million compared to CNY 501.361 million a year ago. Basic earnings per share from continuing operations was CNY 1.1719 compared to CNY 0.808 a year ago. Diluted earnings per share from continuing operations was CNY 1.1578 compared to CNY 0.808 a year ago.
Dean Diagnostic Technology Group Co., Ltd. is a company providing integrated solutions for medical diagnosis. The Company's main business involves inspection services, product services, health management, judicial expertise, contract research organization (CRO), cold chain logistics and other fields. The Company's business is mainly oriented to medical and health institutions at all levels, such as various general and specialized hospitals, community health service centers, township (town) health centers, physical examination centers, disease prevention and control centers, etc. The Company's products include Atomic Bomb in the field of liquid phase mass spectrometry, Hydrogen Bomb in the field of nucleic acid mass spectrometry, and Man-Made Satellite in the field of pathological diagnosis products and molecular diagnosis products, and others.
DIAN DIAGNOSTICS GROUP CO.,LTD. 
